Rakovina Therapeutics Inc. Announces Presentation of Second Abstract at the 2025 Society for Neuro-Oncology Annual Meeting

Executive Summary

• Rakovina Therapeutics presented a second scientific abstract at the 2025 Society for Neuro‑Oncology (SNO) Annual Meeting, detailing AI‑driven discovery of novel CNS‑penetrating PARP1‑selective inhibitors.
• The study employed Deep Docking™ and generative‑AI to screen large libraries, synthesize hundreds of prioritized compounds, and identify a subset with selective PARP1 activity and favorable ADME/pharmacokinetic profiles.
• Early data demonstrate the platform’s ability to generate CNS‑penetrant DDR therapeutics, supporting continued optimization toward preclinical/clinical development.

Key Details

• Presentation: Poster titled “Discovery and development of novel CNS‑penetrating PARP1‑selective inhibitors” at SNO 2025 (Nov 19‑23, Honolulu, HI).
• Collaboration: Conducted with investigators from the Vancouver Prostate Centre and the University of British Columbia.
• AI Methodology: Utilized Deep Docking™ and generative‑AI to virtually screen large chemical libraries for compounds predicted to:
• Selectively inhibit PARP1
• Exhibit drug‑like properties suitable for CNS exposure
• Compound Synthesis & Screening:
• Hundreds of prioritized molecules synthesized.
• Biochemical assays identified a subset with confirmed PARP1‑selective activity.
• ADME/PK Findings (first round):
• Demonstrated in vitro metabolic stability and pharmacokinetic profiles favorable for CNS penetration.
• Comparative data presented versus existing PARP inhibitors and next‑generation benchmark compounds.
• Program Implications: Results will guide further optimization, additional in‑vitro/in‑vivo testing, and inform the path toward IND‑enabling studies.
• Quote (President): “The data generated to date provide early insight into our AI‑driven discovery platform… These results demonstrate timely progress of our PARP1‑selective inhibitor program and validate our iterative AI approach.” – Prof. Mads Daugaard, President, Rakovina Therapeutics.

Notable Quotes

• Prof. Mads Daugaard, President: “The data generated to date provide early insight into our AI‑driven discovery platform and its ability to prioritize compounds with the features we are seeking, including PARP1 selectivity and properties supportive of CNS penetration.”